Advanced Filters
noise

melanoma Clinical Trials

A listing of melanoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 470 clinical trials
M Malik Hall

Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma

This is a prospective phase II multi-center trial of the combination of the PARP inhibitor olaparib with the immune checkpoint inhibitor pembrolizumab in advanced uveal melanoma.

18 years of age All Phase 2
J Jun Guo, Director

A Study of IBI363 in Subjects With Advanced Melanoma

This is an open-lable, multicenter Phase II study to evaluate the safety, tolerability, and efficacy of IBI363 in advanced melanoma patients

18 years of age All Phase 2
R Rita Mehta, MD

Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma

This is a phase 2, single-arm, open label clinical trial determining efficacy of Cyclophosphamide and Pembrolizumab in subjects with melanoma.

18 years of age All Phase 2
O Olena Glushakova

FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma

This study is for adult patients with advanced melanoma who are receiving immunotherapy and who are planning on having surgery for their cancer. All participants in this study will receive an experimental treatment made up of focused ultrasound ablation (FUSA), a non-invasive experimental treatment that uses ultrasound waves to heat …

18 years of age All Phase N/A
S Sally Haines, BNurs. GradCert (Pall.Care)

Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases

Single arm phase I/II trial to evaluate the safety and efficacy of the combination of bevacizumab, with ipilimumab plus nivolumab, and hypofractionated stereotactic radiotherapy (hSRT) in patients with symptomatic melanoma brain metastases (MBM).

18 years of age All Phase 1/2

Neoadjuvant Pembrolizumab in Patients With Stage IIb/c Melanoma

A phase II double-blind placebo-controlled randomized trial. Patients with a clinical suspicion of a thick primary melanoma without clinical suspicion or evidence of lymph-node engagement will undergo a 3 mm punch biopsy to verify the diagnosis and ascertain eligibility. Patients will receive 1 cycle of pembrolizumab 400 mg or placebo …

18 years of age All Phase 2
Y Yvonne LaFary

A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

KB707-01 is a Phase 1, open-label, multicenter, dose escalation and expansion study to evaluate the safety and tolerability of KB707 in adults with locally advanced or metastatic solid tumors who have progressed on standard of care therapy, cannot tolerate standard of care therapy, refused standard of care therapy, or for …

18 years of age All Phase 1
G Grant A McArthur, MBBS, PhD

Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE

This is an open-label, phase IB, non-randomised study consisting of a dose escalation phase and expansion phase, evaluating the safety, tolerability and preliminary efficacy of the combination of encorafenib, binimetinib and palbociclib in patients with BRAF-mutant metastatic melanoma. Dose escalation phase: Previously treated or treatment-naïve patients will be evaluated after …

18 - 100 years of age All Phase 1/2
A Ann Lau Clark, RN, MSN

Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes

Phase I clinical trial to determine the Phase II dose of autologous TIL 1383I TCR gene modified T Cells using a retrovirus. This is a novel National Cancer Institute (NCI) funded investigator initiated therapy for patients with advanced melanoma.

18 - 89 years of age All Phase 1
K Katarzyna Smolarczyk

Stereotactic Ablative Radiotherapy (XRT) and Immunotherapy for Oligometastatic Extracranial Melanoma

The purpose of this research is to evaluate the addition of radiotherapy to the standard immunotherapy drugs that are given to patients with advanced or metastatic melanoma that has spread to other parts of the body. Radiotherapy uses x-rays to target and kill melanoma cells and immunotherapy works by activating …

18 years of age All Phase N/A

Simplify language using AI